前往化源商城

Journal of Immunology 2014-12-01

T-bet:Eomes balance, effector function, and proliferation of cytomegalovirus-specific CD8+ T cells during primary infection differentiates the capacity for durable immune control.

Iulia Popescu, Matthew R Pipeling, Pali D Shah, Jonathan B Orens, John F McDyer

文献索引:J. Immunol. 193(11) , 5709-22, (2014)

全文:HTML全文

摘要

CMV remains an important opportunistic pathogen in solid organ transplantation, particularly in lung transplant recipients (LTRs). LTRs mismatched for CMV (donor+/recipient-; D+R-) are at high-risk for active CMV infection and increased mortality, however the immune correlates of viral control remain incompletely understood. We prospectively studied 23 D+R- LTRs during primary CMV infection to determine whether acute CD8(+) T cell parameters differentiated the capacity for viral control in early chronic infection. T-box transcription factors expression patterns of T-bet > Eomesodermin (Eomes) differentiated LTR controllers from viremic relapsers and reciprocally correlated with granzyme B loading, and CMV phosphoprotein 65 (pp65)-specific CD8(+)IFN-γ(+) and CD107a(+) frequencies. LTR relapsers demonstrated reduced CD8(+)Ki67(+) cells ex vivo and substantially impaired CD8(+)pp65-specific in vitro proliferative responses at 6 d, with concomitantly lower pp65-specific CD4(+)IL-2(+) frequencies, as compared with LTR controllers. However, CMV-specific in vitro proliferative responses could be significantly rescued, most effectively with pp65 Ag and exogenous IL-2, resulting in an increased T-bet:Eomes balance, and enhanced effector function. Using class I CMV tetramers, we observed similar frequencies between relapsers and controllers, although reduced T-bet:Eomes balance in tetramer(+) cells from relapsers, along with impaired CD8(+) effector responses to tetramer-peptide restimulation. Taken together, these data show impaired CMV-specific CD8(+) effector responses is not for complete lack of CMV-specific cells but rather underscores the importance of the T-bet:Eomes balance, with CMV-specific proliferation a key factor driving early T-bet expression and effector function in CD8(+) T cells during primary infection and differentiating the capacity of high-risk LTRs to establish immune control during early chronic infection. Copyright © 2014 by The American Association of Immunologists, Inc.

相关化合物

结构式 名称/CAS号 全部文献
布雷菲德菌素A 结构式 布雷菲德菌素A
CAS:20350-15-6
5-(((2,5-二氧吡咯烷-1-基)氧基)羰基)-3-羰基-3H-螺-[异苯并呋喃-1,9'-氧杂蒽]-3',6'-二基 二乙酸酯 结构式 5-(((2,5-二氧吡咯烷-1-基)氧基)羰基)-3-羰基-3H-螺-[异苯并呋喃-1,9'-氧杂蒽]-3',6'-二基 二乙酸酯
CAS:150206-05-6
异丙基亚硫酸锌 结构式 异丙基亚硫酸锌
CAS:1416821-55-0
5(6)-羧基二乙酸荧光素琥珀酰亚胺酯(CFDA) 结构式 5(6)-羧基二乙酸荧光素琥珀酰亚胺酯(CFDA)
CAS:150347-59-4